Until only recently, treating Glioblastoma brain cancer with chemotherapy has not been achievable due to the blood brain barrier.  In today’s Bindwaves episode, Dr. Michael Canney walks us through how Carthera developed a revolutionary method to deliver therapeutics to the brain utilizing an ultrasound system.  It is well known that the survival rate for Glioblastoma is 1 to 2 years.  Surgery tends to be the primary means to combat this horrible disease.  To improve these odds, an ultrasound implant is placed in the brain after the surgeon removes the tumor.  This implant, or mesh, contains an ultrasound transducer, which when activated during chemo treatments, disrupts the blood brain barrier thus allowing therapeutics to attach to the cancer cells.   Join us as Dr. Canney eloquently discusses the history of this treatment, Phase 1 and Phase 2 results, and their hopes for the Phase 3 trial. 

Send us a text

Support the show

You can find this episode’s transcript here.
New episodes drop every other Thursday everywhere you listen to podcasts.

🎙️ Do you want to support us?

• Give us some feedback, tell us what bindwaves has meant for you by emailing us at [email protected]
• Leave us a rating or review on Apple Podcasts and Spotify
• Share episodes with your friends!
• Make a monthly or one time donation at www.thebind.org
• Follow bindwaves on Instagram, Facebook, and YouTube!

🧑‍💻Visit our website! thebind.org/bindwaves